Monograph Details
|
|
Urogenital System
> Benign prostatic hyperplasia/urinary retention
|
|
UROXATRAL |
| Manufacturer |
|
Sanofi Aventis |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
α1-blocker (quinazoline). |
| Generic Name |
|
Alfuzosin 10mg; ext-rel tabs. |
| Indications |
|
BPH. |
| Children |
|
Not applicable. |
| Adults |
|
Swallow whole; take immediately after same meal each day. 10mg once daily. |
| Contraindications |
|
Concomitant potent CYP3A4 inhibitors (eg, ketoconazole, itraconazole, ritonavir). Moderate or severe hepatic insufficiency. Not for use in children or women. |
| Precautions |
|
Discontinue if angina develops or worsens. Severe renal insufficiency (CrCl <30mL/min). Hypotension. Mild hepatic impairment. History of QT interval prolongation. Exclude prostate cancer. Cataract surgery (intraoperative floppy iris syndrome possible). |
| Interactions |
|
See Contraindications. Do not use with other α-blockers. Potentiates and is potentiated by cimetidine. Potentiates cardiovascular effects of atenolol. Caution with antihypertensives, moderate CYP3A4 inhibitors (eg, diltiazem), and with drugs that prolong QT interval. |
| Adverse Reactions |
|
Postural hypotension, dizziness, upper respiratory tract infection, headache, fatigue, GI upset, impotence, syncope. |
| How Supplied |
|
Tabs—30, 100 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
